NOTRIXUM®
(pazopanib, as hydrochloride)
TEVA
HK Reg. No. HK-68611 (13 Mar, 2025)
Composition:3
• Pazopanib is available as 200 mg film-coated tablets
Indication:3
Pazopanib (Teva) is indicated for:
• Treatment of advanced and/or metastatic renal cell carcinoma
• Treatment of advanced (unresectable and/or metastatic) soft tissue sarcoma in patients who, unless otherwise contraindicated, have received prior chemotherapy including an anthracycline treatment
References
3. Medsafe (New Zealand Medicines and Medical Devices Safety Authority). NEW ZEALAND DATA SHEET. Available from: https://www.medsafe.govt.nz/profs/datasheet/p/PazopanibTab.pdf. [Accessed 16 May 2025].
